Literature DB >> 17239042

How many long-stay schizophrenia patients can be discharged in Japan?

Iwao Oshima1, Yoshio Mino, Yoshimasa Inomata.   

Abstract

The mental health-care system in Japan remains hospital-based, and has the largest number of psychiatric beds per capita in the world. However, serious discussion about deinstitutionalization has recently begun. This study attempts to determine the proportion of inpatients that would benefit from community-based programs, as judged by hospital psychiatrists, and to evaluate the need for community resources for their community placement. Inpatients with schizophrenia from 139 hospitals were randomly selected. Data on the psychiatrists' judgment of discharge and required resources for community placement were obtained for 2758 subjects. Among the subjects, 1097 (39.8%) were judged to have the possibility of being discharged using community resources (possible discharge group; PDG). Provided that the proportion of PDG was 40%, controlling for the hospital background variables, the number of schizophrenia inpatients with a hospital stay of > or = 1 year who could be discharged from psychiatric hospitals in Japan was estimated to be 66,000. For the PDG, the required community resources, including accommodation, daytime activity, and daily living support services, were calculated. The numbers of governmental targets for community resources, including community accommodation, daytime activities, and daily living support services may have been underestimated.

Entities:  

Mesh:

Year:  2007        PMID: 17239042     DOI: 10.1111/j.1440-1819.2007.01613.x

Source DB:  PubMed          Journal:  Psychiatry Clin Neurosci        ISSN: 1323-1316            Impact factor:   5.188


  12 in total

1.  Comprehensive early intervention for patients with first-episode psychosis in Japan (J-CAP): study protocol for a randomised controlled trial.

Authors:  Shinsuke Koike; Atsushi Nishida; Syudo Yamasaki; Kayo Ichihashi; Sanae Maegawa; Tatsunobu Natsubori; Hirohiko Harima; Kiyoto Kasai; Izumi Fujita; Masanori Harada; Yuji Okazaki
Journal:  Trials       Date:  2011-06-20       Impact factor: 2.279

2.  Readiness to quit as a predictor for outcomes of smoking-reduction programme with transdermal nicotine patch or bupropion in a sample of 308 patients with schizophrenia.

Authors:  Kuan-Ju Chou; Hsing-Kang Chen; Chih-Hung Hung; Tzu-Ting Chen; Chun-Ming Chen; Bo-Jian Wu
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-07-09       Impact factor: 5.270

3.  Application of Level of Care Utilization System for Psychiatric and Addiction Services (LOCUS) to psychiatric practice in Japan: a preliminary assessment of validity and sensitivity to change.

Authors:  Taku Kimura; Fukashi Yagi; Akira Yoshizumi
Journal:  Community Ment Health J       Date:  2012-11-29

4.  Comparison of prevalence of metabolic syndrome in hospital and community-based Japanese patients with schizophrenia.

Authors:  Norio Sugawara; Norio Yasui-Furukori; Yasushi Sato; Ikuko Kishida; Hakuei Yamashita; Manabu Saito; Hanako Furukori; Taku Nakagami; Mitsunori Hatakeyama; Sunao Kaneko
Journal:  Ann Gen Psychiatry       Date:  2011-09-12       Impact factor: 3.455

5.  Predictors of continuation with olanzapine during the 1-year naturalistic treatment of patients with schizophrenia in Japan.

Authors:  Wenyu Ye; Haya Ascher-Svanum; Yuka Tanji; Jennifer A Flynn; Michihiro Takahashi
Journal:  Patient Prefer Adherence       Date:  2011-12-14       Impact factor: 2.711

6.  Association between length of hospital stay and implementation of discharge planning in acute psychiatric inpatients in Japan.

Authors:  Miharu Nakanishi; Junko Niimura; Michika Tanoue; Motoe Yamamura; Toyoaki Hirata; Nozomu Asukai
Journal:  Int J Ment Health Syst       Date:  2015-05-30

7.  Modeling the budget impact of long-acting injectable paliperidone palmitate in the treatment of schizophrenia in Japan.

Authors:  Jörg Mahlich; Masamichi Nishi; Yoshimichi Saito
Journal:  Clinicoecon Outcomes Res       Date:  2015-05-22

8.  One-year outcomes in schizophrenia after switching from typical antipsychotics to olanzapine in Japan: an observational study.

Authors:  Wenyu Ye; Shinji Fujikoshi; Naohiro Nakahara; Michihiro Takahashi; Haya Ascher-Svanum; Tetsuro Ohmori
Journal:  Pragmat Obs Res       Date:  2012-06-13

9.  Hannover study on long-stay hospitalization - part II: Characteristics and care conditions of long-stay hospitalization in cases of chronic mental illness.

Authors:  Stefan M Bartusch; Bernd R Brüggemann; Hermann Elgeti; Marc Ziegenbein; Wielant Machleidt
Journal:  Clin Pract Epidemiol Ment Health       Date:  2007-11-26

10.  Psychiatrists' attitudes toward metabolic adverse events in patients with schizophrenia.

Authors:  Norio Sugawara; Norio Yasui-Furukori; Manabu Yamazaki; Kazutaka Shimoda; Takao Mori; Takuro Sugai; Yutaro Suzuki; Toshiyuki Someya
Journal:  PLoS One       Date:  2014-01-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.